Compare Stocks: KROS, OLMA, CADL, and GERN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.84 -0.1%	$11.27	$4.35 ▼ $14.00	$829.09M	-0.48	1.19 million shs	3.01 million shs
GERN Geron	$1.30	$1.46	$1.04 ▼ $2.01	$835.21M	0.61	10.87 million shs	17.24 million shs
KROS Keros Therapeutics	$11.19	$10.78	$9.69 ▼ $22.55	$221.86M	1.01	175,113 shs	302,476 shs
OLMA Olema Pharmaceuticals	$9.82	$11.00	$6.65 ▼ $36.26	$859.25M	1.98	982,780 shs	3.06 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+2.70%	-17.48%	+18.42%	+125.26%
GERN Geron	0.00%	-3.70%	-14.47%	-2.99%	-1.52%
KROS Keros Therapeutics	0.00%	+0.99%	+1.45%	+1.91%	-28.08%
OLMA Olema Pharmaceuticals	0.00%	-3.91%	-8.14%	-1.80%	+20.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.84 -0.1%	$11.27	$4.35 ▼ $14.00	$829.09M	-0.48	1.19 million shs	3.01 million shs
GERN Geron	$1.30	$1.46	$1.04 ▼ $2.01	$835.21M	0.61	10.87 million shs	17.24 million shs
KROS Keros Therapeutics	$11.19	$10.78	$9.69 ▼ $22.55	$221.86M	1.01	175,113 shs	302,476 shs
OLMA Olema Pharmaceuticals	$9.82	$11.00	$6.65 ▼ $36.26	$859.25M	1.98	982,780 shs	3.06 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+2.70%	-17.48%	+18.42%	+125.26%
GERN Geron	0.00%	-3.70%	-14.47%	-2.99%	-1.52%
KROS Keros Therapeutics	0.00%	+0.99%	+1.45%	+1.91%	-28.08%
OLMA Olema Pharmaceuticals	0.00%	-3.91%	-8.14%	-1.80%	+20.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.64	Moderate Buy	$19.29	77.99% Upside
GERN Geron	2.20	Hold	$4.00	207.69% Upside
KROS Keros Therapeutics	2.33	Hold	$20.50	83.20% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	313.44% Upside

Current Analyst Ratings Breakdown

Latest KROS, OLMA, CADL, and GERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/12/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
GERN Geron	$183.88M	4.54	N/A	N/A	$0.35 per share	3.71
KROS Keros Therapeutics	$15.01M	14.78	$4.53 per share	2.47	$15.51 per share	0.72
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	21.67	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	11/4/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)

Latest KROS, OLMA, CADL, and GERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.38	16.09	16.09
GERN Geron	0.55	6.91	5.16
KROS Keros Therapeutics	N/A	21.96	21.96
OLMA Olema Pharmaceuticals	0.01	8.86	8.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
GERN Geron	73.71%
KROS Keros Therapeutics	71.56%
OLMA Olema Pharmaceuticals	91.78%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
GERN Geron	1.71%
KROS Keros Therapeutics	12.60%
OLMA Olema Pharmaceuticals	12.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
GERN Geron	258	642.47 million	631.49 million	Optionable
KROS Keros Therapeutics	92	19.83 million	17.33 million	Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable

KROS, OLMA, CADL, and GERN Headlines

Recent News About These Companies

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts

September 19 at 4:13 AM | marketbeat.com

Stifel Nicolaus Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)

September 17, 2026 | theglobeandmail.com

Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results

September 14, 2026 | finance.yahoo.com

Citi Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

September 12, 2026 | theglobeandmail.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 4.4% - Here's Why

September 11, 2026 | marketbeat.com

Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Squarepoint Ops LLC

September 11, 2026 | marketbeat.com

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 3.5% - Should You Buy?

September 10, 2026 | marketbeat.com

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27

September 9, 2026 | seekingalpha.com

Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA

September 9, 2026 | marketbeat.com

Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA

September 7, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA

September 7, 2026 | marketbeat.com

Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne

September 2, 2026 | quiverquant.comQ

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Olema Oncology to Participate in Upcoming Investor Conferences

August 31, 2026 | globenewswire.com

BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA

August 30, 2026 | marketbeat.com

Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA

August 27, 2026 | marketbeat.com

Bank of America Corp DE Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA

August 26, 2026 | marketbeat.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 25, 2026 | marketbeat.com

Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

August 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, OLMA, CADL, and GERN Company Descriptions

Candel Therapeutics NASDAQ:CADL

$10.84 -0.02 (-0.14%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$10.96 +0.13 (+1.18%)

As of 04:08 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Geron NASDAQ:GERN

$1.30 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.30 0.00 (0.00%)

As of 04:06 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Keros Therapeutics NASDAQ:KROS

$11.19 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.32 +0.13 (+1.12%)

As of 04:08 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Olema Pharmaceuticals NASDAQ:OLMA

$9.82 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.85 +0.03 (+0.25%)

As of 04:01 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KROS, OLMA, CADL, and GERN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KROS, OLMA, CADL, and GERN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KROS, OLMA, CADL, and GERN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, OLMA, CADL, and GERN Company Descriptions

Candel Therapeutics NASDAQ:CADL

Geron NASDAQ:GERN

Keros Therapeutics NASDAQ:KROS

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KROS, OLMA, CADL, and GERN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KROS, OLMA, CADL, and GERN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KROS, OLMA, CADL, and GERN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, OLMA, CADL, and GERN Company Descriptions

Candel Therapeutics NASDAQ:CADL

Geron NASDAQ:GERN

Keros Therapeutics NASDAQ:KROS

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools